ClinicalTrials.gg
Active, not recruitingNCT06421636FERVENT-1Updated Jul 1, 2026

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

A Phase 2 interventional study of REGN7999 and Placebo in Non-Transfusion Dependent Beta-Thalassemia (NTDT), sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 26 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is.

The study is looking at several other research questions, including:

  • Whether the study drug lowers extra iron levels in the body
  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
02

Conditions studied

  • Non-Transfusion Dependent Beta-Thalassemia (NTDT)

Browse trials for

Keywords

  • Beta-Thalassemia
  • Resultant Iron Overload (IOL)
03

In context

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

This study's enrollment of 19 is below the median of 40 across 208 interventional studies indexed under beta-Thalassemia.

Browse beta-Thalassemia studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Clinical diagnosis of NTDT as described in the protocol
  2. IOL, defined as LIC ≥ 5 mg Fe/g DW as measured by R2* MRI at screening
  3. Serum ferritin ≥ 300 ng/mL as described in the protocol

Key Exclusion Criteria:

  1. ≤ 8 g/dL at screening
  2. Any RBC transfusion within 12 weeks of visit 3
  3. For Part A only: Any Iron Chelation Therapy (ICT) use in approximately 12 weeks prior to screening as described in the protocol
  4. For Part B only: If on ICT, any change in ICT dose in approximately 12 weeks prior to screening as described in the protocol
  5. Any use of luspatercept or mitapivat in 6 months prior to screening as described in the protocol
  6. Absolute to MRI
  7. Diagnosis of cirrhosis of the liver
  8. Diagnosis of Chronic kidney disease (CKD) stage 4 or higher

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Part A High Dose

    Randomized 2:2:1

    Drug: REGN7999

  • Experimental
    Part A Low Dose

    Randomized 2:2:1

    Drug: REGN7999

  • Placebo comparator
    Part A Placebo

    Randomized 2:2:1

    Drug: Placebo

  • Experimental
    Part B High Dose

    Randomized 2:2:1

    Drug: REGN7999

  • Experimental
    Part B Low Dose

    Randomized 2:2:1

    Drug: REGN7999

  • Placebo comparator
    Part B Placebo

    Randomized 2:2:1

    Drug: Placebo

Interventions

  • DrugREGN7999

    Administered subcutaneous (SC)

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change from baseline in Liver Iron Concentration (LIC) by R2* Magnetic Resonance Imaging (MRI)

    Time frame: At week 24

  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to week 72

  3. Severity of TEAEs

    Time frame: Up to week 72

Secondary outcomes

  1. Achievement of ≥20% reduction from baseline in LIC by R2* MRI

    Time frame: Through week 52

  2. Change from baseline in hemoglobin

    Time frame: To week 24

  3. Change from baseline in LIC by R2* MRI

    Time frame: At week 52

  4. Percent change from baseline in LIC by R2* MRI

    Time frame: To week 24 and week 52

  5. Achievement of ≥20% reduction from baseline in LIC by R2* MRI

    Time frame: Through week 24

  6. Change in hemoglobin over time

    Time frame: Up to week 56

  7. Achievement of ≥1.5 g/dL increase in hemoglobin for two consecutive assessments in the absence of Red Blood Cell (RBC) transfusions

    Time frame: Baseline to week 56

  8. Number of RBC transfusions required

    Time frame: Baseline to week 72

  9. Achievement of transfusion independence

    Time frame: Baseline to week 72

  10. Change in RBC counts over time

    Time frame: Baseline to week 56

  11. Concentrations of REGN7999 in serum over time

    Time frame: Up to week 56

  12. Incidence of Anti-Drug Antibody (ADA) to REGN7999 over time

    Time frame: Up to week 56

  13. Magnitude of ADA to REGN7999 over time

    Time frame: Up to week 56

07

Study locations

26 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 29 phase 2 interventional studies under beta-Thalassemia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 20, 2024
StartActual
Sep 30, 2024
Primary completionEst.
Dec 3, 2026
CompletionEst.
Dec 3, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06421636
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Sep 30, 2024
Primary completion
Dec 3, 2026 (estimated)
Completion
Dec 3, 2026 (estimated)
Last update
Jul 1, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion